Empowering health
SUL-238 in Phase I
This week, the first dosings of SUL-238 in healthy volunteers in a Phase I study marks a major milestone in the clinical development of this hibernation-derived, first-in-class drug. The phase I study investigates the safety, tolerability and pharmacokinetics after single and repeated doses of SUL-238 in human as the first step towards patient benefit.
About Sulfateq B.V.
Sulfateq BV is an innovative privately-held biotechnology company that is developing breakthrough compounds for the treatment of a wide range of therapeutic indications related to mitochondrial dysfunction. Our compound library emerged from research on natures natural mechanisms to cope with mitochondrial stress, including hibernation. SUL compounds have an unique mechanism-of-action and the potential to revolutionize the standard-of-care of diseases associated with a declined mitochondrial function.
We strongly believe in the potential of our science to deliver new treatments and improve quality of life for patients with non-communicable diseases involving mitochondrial dysfunction.
We are always open for new innovative partnerships. Please contact us to discuss the opportunities.
SUL-238, a first-in-class medicine, protects from ageing
We are happy to share great news! SUL-238 is currently in Phase I clinical trials in collaboration with our Turkish partner GEN Ilac. It is the first drug reported that leads to persisting improvement of vascular aging. This work has recently been published in The...
Sulfateq B.V.